Skip to main content
Purple Biotech Ltd. logo

Purple Biotech Ltd. — Investor Relations & Filings

Ticker · PPBT ISIN · IL0007650166 TA Manufacturing
Open in API
Filings indexed 1,071 across all filing types
Latest filing 2024-12-02 Regulatory Filings
Country IL Israel
Listing TA PPBT

About Purple Biotech Ltd.

https://purple-biotech.com/

Purple Biotech Ltd. is a clinical-stage company that develops first-in-class therapies for cancer patients. The company focuses on advancing treatments designed to overcome tumor immune evasion and drug resistance, with the goal of providing effective and durable therapeutic solutions.

Recent filings

Filing Released Lang Actions
6K- Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer
Regulatory Filings Classification · 98% confidence The document is explicitly titled 'FORM 6-K' and is filed 'For the month of December 2024' by a 'Foreign Private Issuer' with the SEC. Form 6-K is used by foreign private issuers to report material information that is required to be publicly disclosed in their home country or stock exchange, or that is distributed to their shareholders. This type of filing is generally considered a miscellaneous regulatory filing that doesn't fit neatly into the primary US periodic reports (like 10-K or 10-Q). Since the content is a press release announcing positive clinical trial results (Exhibit 99.1), and the Form 6-K itself is the mechanism of submission, the most appropriate classification among the provided options for a non-standard, material regulatory disclosure is 'Regulatory Filings' (RNS), as it serves as a general catch-all for required disclosures that aren't covered by the more specific categories like ER, IR, or 10-K. It is not an Earnings Release (ER) as it focuses on clinical data, not quarterly financials, nor is it a comprehensive Interim Report (IR).
2024-12-02 English
6K- Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer
Report Publication Announcement Classification · 98% confidence The document is very short (2205 characters) and explicitly states, "Attached hereto is a report on*6K: Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer*" followed by a PDF filename. This structure indicates that the document itself is an announcement about the publication of another report (a 6-K filing, which is an 'Other Report' under SEC rules, often used for material non-public information). According to Rule 2, when a document is short and announces the availability of a report, it should be classified as a Report Publication Announcement (RPA). The content is an immediate report filed with the Israel Securities Authority and Tel Aviv Stock Exchange, but the document's function here is to announce the attached 6-K, making RPA the most appropriate classification based on the provided definitions and rules.
2024-12-02 English
Reports Third Quarter 2024 Financial Results
Earnings Release Classification · 98% confidence The document is explicitly titled 'FORM 6-K' and states it is a 'Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934' for the month of November 2024. The content is a press release announcing the 'Third Quarter 2024 Financial Results' and business highlights. A Form 6-K is typically used to report material information that a foreign private issuer is required to disclose to its home country or stock exchange, or that it voluntarily discloses to the SEC. Since this filing contains the detailed financial results for a specific period (Q3 2024), it functions as an official periodic report disclosure. While it contains an Earnings Release (ER) summary, the overall filing structure (Form 6-K incorporating a press release) is a regulatory filing mechanism. Given the options, this is best classified as a general Regulatory Filing (RNS) or, more specifically, if the content strongly mirrors an Interim Report, IR. However, Form 6-K is a broad SEC filing category. Since the content is a comprehensive announcement of quarterly results, it aligns closely with the function of an Interim/Quarterly Report (IR) but is submitted via the 6-K mechanism. Because the document is a full SEC filing (Form 6-K) containing the results, and not just a short announcement linking to the results (which would be RPA/RNS), we must choose the most appropriate content category. The content is a detailed summary of Q3 2024 results, which fits the description of an Interim / Quarterly Report (IR). However, Form 6-K is a general filing. Given the options, and recognizing that 6-K is a mechanism rather than a content type listed, we look at the content: it reports on Q3 2024 results. If the document were a full 10-Q, it would be IR. Since it's a 6-K containing the Q3 results, it is a regulatory filing that reports periodic results. Since 'IR' is defined as a 'Comprehensive financial report for a period shorter than a year (e.g., half-year)', and this document provides the Q3 results, IR is a strong candidate for the content type. However, the primary identifier is the SEC Form 6-K, which is a general reporting requirement. In many databases, 6-K filings are categorized under a general regulatory filing code if a specific content code doesn't perfectly map. Given the comprehensive nature of the financial data presented (even if summarized), it is more than just an ER. It is a disclosure of quarterly performance. I will classify it as IR based on content, but acknowledge the 6-K wrapper. Given the options, and the fact that it details the Q3 results, IR is the best fit for the *information* being conveyed, even though the *form* is 6-K. If 6-K were an option, it would be chosen. Since it is not, and it contains detailed quarterly financial reporting, IR is selected over RNS (general fallback). The document length is substantial (42k chars), ruling out RPA/RNS based on the 'MENU VS MEAL' rule for short announcements. Q3 2024
2024-11-16 English
Reports Third Quarter 2024 Financial Results
Report Publication Announcement Classification · 98% confidence The document is a formal filing notification to the Israel Securities Authority and the Tel Aviv Stock Exchange. It explicitly states: "Report of Periodic or Interim Report" and references the reporting period ending 30.9.24 (Third Quarter). Crucially, the text contains the phrase: "Attached hereto is 6K: Purple Biotech Reports Third Quarter 2024 Financial Results" followed by a reference to an attached PDF file. Since the document itself is short (2181 chars) and serves primarily to announce the publication of the actual financial results (which would be the Interim Report, IR), it fits the definition of a Report Publication Announcement (RPA) based on the 'MENU VS MEAL' rule. If the attached document were provided, it would be classified as IR, but this notification is the announcement of that report.
2024-11-16 English
Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death
Regulatory Filings Classification · 98% confidence The document is explicitly titled 'FORM 6-K' and is a 'Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934'. Form 6-K filings are used by foreign private issuers to report material information that they are required to disclose to their home country's securities regulator or stock exchange, or that they make public in their home country. This type of filing is generally used for current material events, which often include press releases about clinical trial updates, business developments, or financial highlights that are not covered by the standard periodic reports (like 20-F). The content is a press release announcing a scientific/clinical finding (biomarker identification for CM24) and is dated November 4, 2024. Since this is a current report of material information that doesn't fit the specific categories like ER (Earnings Release), IR (Interim Report), or DIV (Dividend Notice), the most appropriate general category for a non-standard, current regulatory disclosure from a foreign issuer is 'Regulatory Filings' (RNS), as it serves as a catch-all for required SEC submissions that aren't the major periodic reports or specific event filings like DEF 14A or 8-K equivalents for foreign issuers. However, looking closely at the provided definitions, RNS is defined as 'General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories.' While Form 6-K is a specific regulatory filing, it is used to disseminate material news, similar to an Earnings Release (ER) or a Capital Update (CAP), but it is not one of those specific types. Given the nature of the content (a press release about a clinical development), it is a material event disclosure. Since there is no specific 'Form 6-K' code, RNS is the best fit as the general regulatory fallback.
2024-11-04 English
Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death
Report Publication Announcement Classification · 98% confidence The document is very short (2271 characters) and explicitly states, "Attached hereto is a report on*6K: Purple Biotech Identifies Potential New Serum Biomarker...*" followed by a PDF filename. This structure indicates that the document itself is an announcement about the publication of another report (a 6-K filing, which is an 'Other Report' under SEC rules, often used for material non-public information by foreign private issuers). Since the text is an announcement pointing to an attached/linked report rather than the full content of a specific periodic report (like 10-K or IR), it fits the definition of a Report Publication Announcement (RPA) or, given the context of a general regulatory filing announcement, potentially RNS. Given the explicit mention of 'Attached hereto is a report on...', RPA is the most precise fit among the provided options for an announcement of a filing/report release.
2024-11-04 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.